Allakos Cutting About 50% of Workforce, Abandons Lirentelimab Development After Failing Inflammatory Testings
Following the strategic restructuring, Allakos reported that Lirentelimab failed in its Phase II studies for atopic dermatitis and chronic spontaneous urticaria. Read more.
Source: jobsnhire.com